首页> 外文期刊>The Journal of toxicological sciences >Characterization of human iPS cell-derived cardiomyocyte sheets as a model to detect drug-induced conduction disturbance
【24h】

Characterization of human iPS cell-derived cardiomyocyte sheets as a model to detect drug-induced conduction disturbance

机译:表征人iPS细胞衍生的心肌细胞片作为检测药物诱导的传导障碍的模型

获取原文
           

摘要

In order to characterize human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) sheets as a model for detecting drug-induced conduction disturbance, we examined their electrophysiological and electropharmacological properties by using the multi-electrode array system with a programmed electrical stimulation protocol. At pre-drug control, the conduction speed, effective refractory period and field potential duration were 0.14 ± 0.01 m/sec, 453 ± 10 msec and 361 ± 9 msec, respectively at a cycle length of 1,000 msec (n = 18). Shortening the pacing cycle length from 1,000 to 600 msec decreased the conduction speed and field potential duration, but prolonged the effective refractory period. Disopyramide, lidocaine and flecainide decreased the conduction speed but prolonged the effective refractory period and field potential duration, whereas the reverse was true for verapamil. Thus, conduction properties of the cell sheet may largely depend on the extent of Na+ channel availability as is the case in the human ventricle. Importantly, there was no relationship between the conduction delay and 1st spike amplitude reduction after the treatment of Na+ channel blockers. These findings may provide crucial guide on future application of this new technology for early phase safety pharmacological screening of new chemical entities.
机译:为了将人类诱导的多能干细胞衍生的心肌细胞(hiPSC-CMs)片表征为检测药物诱导的传导障碍的模型,我们通过使用具有可编程电刺激方案的多电极阵列系统检查了它们的电生理和电药理特性。在药物前控制下,在1,000毫秒的周期长度(n = 18)下,传导速度,有效不应期和电场电位持续时间分别为0.14±0.01 m / sec,453±10 msec和361±9 msec。将起搏周期长度从1000毫秒缩短到600毫秒会降低传导速度和场电势持续时间,但会延长有效不应期。双吡amide酰胺,利多卡因和氟卡尼降低了传导速度,但延长了有效不应期和电场电位持续时间,而维拉帕米则相反。因此,细胞片的传导特性可能很大程度上取决于Na + 通道的可用性程度,就像人的心室一样。重要的是,Na + 通道阻滞剂治疗后,传导延迟与1 st 尖峰幅度减小之间没有关系。这些发现可能为该新技术在新化学实体的早期安全药理筛选中的未来应用提供关键指导。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号